Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

BACKGROUND: In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration–approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekulic, Aleksandar, Migden, Michael R., Basset-Seguin, Nicole, Garbe, Claus, Gesierich, Anja, Lao, Christopher D., Miller, Chris, Mortier, Laurent, Murrell, Dedee F., Hamid, Omid, Quevedo, Jorge F., Hou, Jeannie, McKenna, Edward, Dimier, Natalie, Williams, Sarah, Schadendorf, Dirk, Hauschild, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433030/
https://www.ncbi.nlm.nih.gov/pubmed/28511673
http://dx.doi.org/10.1186/s12885-017-3286-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433030/
https://www.ncbi.nlm.nih.gov/pubmed/28511673
http://dx.doi.org/10.1186/s12885-017-3286-5

Ejemplares similares